Lupus

Individuals with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis have almost comparable survival rates to those of the general population, Greek study findings indicate.

Findings from the phase 2 NOBILITY trial suggest that the addition of the type II anti-CD20 antibody obinutuzumab to standard therapy may improve renal outcomes for patients with proliferative lupus nephritis.

Adding the calcineurin inhibitor voclosporin to background immunosuppressive therapy improves renal response rates among people with lupus nephritis, show phase 3 trial results published in The Lancet.

African–American women with systemic lupus erythematosus have an increased risk for delivering preterm or small for gestational age infants, even in the years immediately before their diagnosis, US study findings indicate.

Expression of the proinflammatory cytokine interleukin-16 strongly correlates with histologic activity in people undergoing treatment for lupus nephritis, shows a longitudinal study of urinary proteomic profiles.

Click through for more information on this announcement